
Hangzhou Tigermed Consulting Co., Ltd. 300347.Sz / 3347.нк

2020 Annual Results



March 2021

Disclaimer



This document is for information purposes only and is not intended to provide any representation, in whole or in part, of the relevant matters. Please refer to the 2020 annual results announcement and other relevant announcements published on the websites of the Shenzhen Stock Exchange (www.szse.cn) and the Stock Exchange of Hong Kong (www.hkexnews.hk) for further information.

All financials disclosed in this document are presented in accordance with International Financial Reporting Standards ("IFRS") except for those specifically noted otherwise.

By reading these materials, you agree to be bound by the following limitations:

The information herein has been prepared by representatives of Hangzhou Tigermed Consulting Co., Ltd. (杭州泰格医药科技股份有限公司, the "Company") solely for your information and have not been independently verified. The information herein does not constitute any recommendation regarding any securities of the Company or any of its subsidiaries.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information, or opinions contained herein. The Company, nor any of their respective affiliates, controlling persons, directors, officers, employees, advisors or representatives shall have any responsibility or liability whatsoever (for negligence or otherwise) for any loss howsoever arising from any use of the information herein or its contents or otherwise arising in connection with the information herein. The information or opinions set out herein may be subject to updating, completion, revision, verification and amendment and such information may change materially without notice and shall only be considered current as of the date hereof. The information herein is based on the economic, regulatory, market and other conditions as in effect on the date hereof. Certain information in the materials contain information may be sourced from third parties, which has not been independently verified by the Company. It should be understood that any subsequent developments may affect the information contained herein, which the Company is not under an obligation to update, revise or affirm.

You acknowledge that you will be solely responsible for your own assessment of the market and the market position of the Company and that you will conduct your own analysis and be solely responsible for forming your own view of the potential future performance of the business of the Company.

Forward-Looking Statements

The information communicated herein may contain certain "forward-looking statements", which are not historical facts but instead include predictions about future events based on our beliefs and information currently made available to us. Although we believe that these predictions are reasonable on the date hereof, future events are inherently uncertain and these forward-looking statements may turn out to be incorrect. Forward-looking statements involve risk and uncertainty by nature because they relate to events and will depend on circumstances that will occur in the future relating to, inter alia, our ability to compete effectively, our ability to develop and market new service offerings, our ability to expand into new markets, the risks associated with listed subsidiaries of the Company, unforeseeable international tensions, regulatory or governmental scrutiny in certain countries, the impact of emergencies and other force majeure events. We undertake no obligations to update forward-looking statements or to adapt them to future events or developments except as required by applicable laws or listing rules. Any investment in any securities issued by the Company will also involve certain risks. There may be additional material risks that are currently not considered to be material or of which the Company and its advisors or representatives are unaware. Against the background of these uncertainties, you should not rely on these forward-looking statements.

Non-IFRS Measure

To supplement our financial information which are presented in accordance with IFRS, we use adjusted net profit attributable to owners of the Company as an additional financial measure, which is not required by, or presented in accordance with IFRS. We define adjusted net profit attributable to owners of the Company as profit for the year attributable to owners of the Company as profit attributable to owners of the Company as profit for the year attributable to owners of the Company as profit attributable to owners of the Company adjusted for (1) share-based compensation expense, (2) net foreign exchange loss/(gain), (3) amortization of intangible assets arising from acquisitions, (4) listing expenses incurred by our Group, and (5) increase in fair value of financial assets at FVTPL. Adjusted net profit attributable to owners of the Company (as determined in accordance with IFRS) as a measure of our operating performance, (ii) cash flows from operating, investing and financing activities as a measure of our ability to meet our cash needs, or (iii) any other measures of performance or liquidity. We believe that this non-IFRS measure is useful for understanding and assessing underlying business performance and operating items that we do not consider indicative of the performance of our business. However, the presentation of this non-IFRS measure is not intended to, and should not, be considered in isolation from or as a substitute for the financial information prepared and presented in accordance with the IFRS. You should not view the non-IFRS measure on a stand-alone basis or as a substitute for results under the IFRS, or as being comparable to results or a similarly titled financial measure reported or forecasted by other companies.

2020 Annual Results



Tigermed 2020 Snapshot





RMB 3,192.3mm Revenue 13.9% YoY Growth

47.1% Gross Margin in 2020 vs **46.1%** in 2019

RMB 987.2mm Adjusted Net Profit Attributable to Owners of the Company⁽¹⁾ **36.9%** YoY Growth

RMB 892.4mm Net Operating Cash Flow 66.0% YoY Growth



Ongoing Project Status⁽²⁾ **389** Drug Clinical Trials **115** Overseas Clinical Trials including **20** MRCTs⁽³⁾

> Extensive Engagement in COVID-19 Related Clinical Trials

1,180 Site Management Projects
665 DMSA⁽⁴⁾ Projects
2,029 Laboratory Services Projects



Business Highlights RMB 7,260.3mm Backlog⁽²⁾ 44.9% YoY Growth

RMB 5,536.5mm New Bookings 30.9% YoY Growth

2,185 Customers Served287 New Customers Added



Corporate Updates 6,032 Total Employees Globally⁽²⁾ 772 Employees Overseas⁽²⁾

Continuing work on ESG profile

Subsidiary DreamCIS Korean IPO in May 2020 Hong Kong H Share IPO in August 2020


Headquarter Relocation and Expansion in Hangzhou in August 2020

(1) Non-IFRS measure


- (3) Multi-regional Clinical Trials
- (4) Data Management and Statistical Analysis

Key Financials Update







Net Profit and Margin



Gross Profit and Margin




Adjusted Net Profit Attributable to the Owners of the Company and Margin⁽¹⁾




Backlog and New Bookings





1H and 2H2020 Revenue by Segment


Total revenue increased 18.0% YoY during 2H2020 vs 9.3% YoY during 1H2020






Revenue Breakdown by PRC and Overseas Markets






Overseas Revenue




Revenue Breakdown by Region



- PRC revenue growth further recovered during 2H2020 benefitting from the effective control of the COVID-19 pandemic in China.
- Overseas revenue up 6.8% YoY, primarily due to the 14.5% YoY growth during 2H2020 (vs -0.6% YoY during 1H2020), as our team worked on more projects and recovered some progress delayed by the pandemic when the COVID-19 situation overseas started to improve since the beginning of 3Q2020.
- RMB appreciated significantly against USD in 2020, which had some negative impact to the growth of our overseas revenue that were mostly generated from projects denominated in USD.

1H and 2H2020 Revenue By Region






Cost of Services




Cost of Services Breakdown by Nature and as % of Revenue




Operating Expenses





Administrative Expenses and as % of Revenue



R&D Expenses and as % of Revenue

124.0


2019



156.6

2020


Share-based Compensation and as % of Revenue



Non-IFRS Adjusted Net Profit Attributable to the Owner of the Company



(RMB mm)



(2) Non-IFRS measure

Business Update




Clinical Trial Solutions ("CTS")




Revenue





Gross Profit and Margin



- The increase of CTS revenue was primarily due to the increased revenue from our clinical trial operation and other services including medical registration, medical translation, and pharmacovigilance etc.
- Acquisition of *Mosim* in January 2020 and *Yaxincheng* in July 2019 also contributed to the increase of the CTS revenue.
- Case-by-case upward re-negotiation of the prices for certain projects with performance obligation beyond the original scope and substantially satisfied in 2019 allowed additional revenue recognized during 1H2020.
- The amount of pass-through fees further decreased in 2020.


Increase of CTS gross profit margin primarily due to:

- Newly acquired *Mosim* and *Yaxincheng* had faster revenue growth and higher gross profit margin in 2020 compared to our clinical trial operation services, which was more adversely impacted by the COVID-19 pandemic.
- Other CTS services, although with a smaller size in terms of revenue, were less impacted by the COVID-19 pandemic (e.g., medical registration and pharmacovigilance) and realized a faster revenue growth and they generally had higher gross profit margins compared to our clinical trial operation services.
- The amount of pass-through fees further decreased in 2020.
- Upward re-negotiation of the prices for certain projects with performance obligation beyond the original scope and substantially satisfied in 2019 allowed additional revenue recognized with low costs during 1H2020.


CTS Key Business Updates

ligermed

Number of Ongoing Drug Clinical Research Projects by Phase⁽¹⁾



Number of Ongoing Drug Clinical Research Projects by Region⁽¹⁾



Medical devices clinical research

- ✓ Completed **74** medical device clinical research projects in 2020, up from 58 in 2019
- ✓ 185 ongoing projects as of December 31, 2020
- ✓ Started to offer IVD development services and pioneered into medical device risk-based monitoring services

Bioequiva

- Completed 82 projects \checkmark
- 144 ongoing projects a \checkmark

alence studies	Other Services
ts in 2020 as of December 31, 2020	 100+ new medical registration projects in 2020 with strong demand in IND and NDA registration services 100+ new projects and 20+ new clients for pharmacovigilance services
	 Medical translation team further expanded to 300+ people

As of year/period end (1)


(2) Others primarily consist of IIT studies and real world studies

Clinical-related and Lab Services ("CRLS")




Revenue

(RMB mm)



Gross Profit and Margin




- The increase of CRLS revenue was primarily driven by the gradual recovery of demand of our laboratory, site management and patient recruitment and DMSA services from our customers, primarily during 2H2020.
- Major CRLS services were broadly adversely impacted by the COVID-19 pandemic. Services in China benefitted from the effective control of the local COVID-19 pandemic and services offered to overseas customers started to recover when the overseas pandemic situation started to improve since 3Q2020.
- Acquisitions made by Frontage contributed to the increase of CRLS revenue.

- Decrease of CRLS gross profit margin primarily due to the decrease in gross profit margin of our laboratory services and site management and patient recruitment services:
- Fixed costs associated with bench scientists, lab facilities and equipment in our laboratory services negatively impacted the gross profit margin when the utility rate decreased due to the COVID-19 pandemic. These fixed costs increased as the capacity and capability for our laboratory services was expanded for future growth strategies in 2020.
- Our sizeable site management and patient recruitment team were unable to operate at a utilization rate comparable to pre-pandemic level because of the pandemic in 2020 and hence reduced the profitability of our site management and patient recruitment services.
- The gross profit margin of DMSA services remained relatively stable in 2020.


CRLS Key Business Updates






Data Management and Statistical Analysis

- Decrease in the number of completed projects in 2020 compared with that in 2019 due to the impact of COVID-19 pandemic
- Ongoing projects increased from 570 as of 30 June 2020 to 665 as of 31 December 2020
- 110+ clients with 600+ professionals in China, South Korea, United States and India
- Registered 35 software copyrights in China in 2020
- Continuing efforts to improve efficiency and level of automation
- EDC System passed ISO9001 / ISO20000 / ISO27001



- Decrease in the number of completed projects in 2020 compared with that in 2019 due to the impact of COVID-19 pandemic
- 400+ new projects acquired in 2020 despite the impact of the COVID-19 pandemic
- Ongoing projects increased from 979 as of 30 June 2020 to 1,180 as of 31 December 2020




- Added >20,000 sq.m lab space for potential expansion in DMPK and Safety and Toxicity business in March 2020
- Acquired US-based Biotranex in March 2020 to further expand DMPK capabilities into transporter analysis, and ACME Biosciences in July 2020 to entered into drug discovery and early development space, which also contributed incremental projects
- Large molecule bioanalytical capability in China upgraded with ELISA, MSD, HTRF and other advanced equipment in July 2020
- Shanghai and Suzhou bioanalytical labs passed NCCL⁽¹⁾ inspection with full marks for three consecutive years in August 2020
- Started to offer preclinical genotoxicity and related safety evaluation in the US, and gene sequencing services in the US bioanalytical lab


Overseas Business Updates



Number of Overseas Employees⁽¹⁾



Number of Ongoing Overseas Drug Clinical Research⁽¹⁾



- Further efforts on overseas clinical operation and global project management capability
 - Expanded clinical operation and project management team in US, Europe and Australia
 - Strategical expansion into LatAm and Africa on the back of COVID-19 related trials
 - Recruited country managers for 7 new countries
 - Geographical coverage of all major continents as of December 31, 2020
- More than RMB300mm MRCT new bookings in 2020
- 95 ongoing single region overseas clinical trials (primarily in South Korea and Australia)
- 20 ongoing MRCTs and a few more to be initiated as of December 31, 2020
 - Covering 21 countries across North America, Asia Pacific, Europe and LatAm
 - 13 therapeutical areas including oncology, rare diseases and vaccines etc.
- Lead CRO for the multi-center phase III clinical study of the Ad5-nCoV vaccine co-developed by CanSino Biologics Inc. and Professor Wei Chen. This is the first China-initiated phase III vaccine clinical study covering multiple continents, including Asia, Europe, and Latin America


Other Business Updates



1	Technology Innovation	 Real-world Study ("RWS") Set up a dedicated RWS team offering retrospective/prospective studies, real world safety monitoring, pharmacoeconomics studies and real-world patient management services in collaboration with internal clinical operation, project management and site management teams Three ongoing real-world studies as of December 31, 2020 Collaboration agreement with <i>Hainan Boao Lecheng Pilot Zone of International Medical Tourism</i> (海南博鳌乐城国际医疗旅游先行区) Further investments in real world evidence related solutions and services Al Call center (智能呼叫中心) Artificial intelligence technology used in the SMO call center, significantly improving the efficiency and optimizing the cost for patient follow-ups
2	Hospital Collaboration	 Excellence for Clinical Trial Sites ("E-Site") Initiatives First batch of five collaborating clinical trial sites and hospitals with 17 Senior Project Management Directors across China Aimed to optimize clinical research resources, improve the infrastructure and technical expertise at sites, and increase the efficiency of patient recruitment and follow-ups Identify future PIs and provide tailored training programs
3	Operational Efficiency	 Continuing investments on infrastructure and operational efficiency Integrated all major subsidiaries across the world within our core database Formulated 5-year plan covering data infrastructure upgrade, analytical and internal decision making framework, and IT upgrade, integration and implementation

Updates of Investment Activities






Employee Base




Total employees increased 13.6% to 6,032 as of December 31, 2020 from 5,312 as of June 30, 2020

Employees Mix by Function as of December 31, 2020

Employees Mix by Geography as of December 31, 2020





Appendix



Consolidated Statement of Profit or Loss



Year ended December 31,

(RMB 000s)	2019	2020
Revenue	2,803,309	3,192,279
Cost of services	(1,511,409)	(1,688,946)
Gross profit	1,291,900	1,503,333
Other income	64,149	145,063
Other gains and losses, net	361,551	1,273,621
Impairment losses	(21,186)	10,075
Selling and marketing expenses	(81,072)	(96,581)
Listing expenses	_	(3,567)
Administrative expenses	(350,510)	(400,749)
Research and development expenses	(124,049)	(156,648)
Share of losses of associates	(9,768)	(3,508)
Finance costs	(42,243)	(50,777)
Profit before tax	1,088,772	2,220,262
Income tax expense	(113,839)	(189,707)
Profit for the year	974,933	2,030,555
Profit attributable to owners of the Company	841,247	1,751,328
Adjusted for:		
Share-based compensation expense	29,733	35,718
Net foreign Exchange loss/(gain)	(6,150)	146,243
Amortization of intangible assets arising from acquisitions	631	6,737
Listing expenses incurred by our Group	5,779	4,991
Change in fair value of financial assets at FVTPL	(150,084)	(957,828)
Adjusted net profit attributable to owners of the Company ⁽¹⁾	721,156	987,189

Consolidated Statement of Financial Position



	As of December 31,	
(RMB 000s)	2019	2020
NON-CURRENT ASSETS	4,201,662	7,862,049
Property, plant and equipment	306,700	400,455
Intangible assets	78,831	124,782
Goodwill	1,157,831	1,444,519
Right-of-use assets	193,420	332,615
Interests in associates	109,713	60,270
Note receivables	735	-
Deferred tax assets	91,476	79,507
Financial assets at fair value through profit or loss ("FVTPL")	2,250,474	5,292,302
Financial assets at fair value through other comprehensive income ("FVTOCI")	-	15,158
Restricted bank deposits	2,093	1,957
Other non-current assets	10,389	110,484
CURRENT ASSETS	3,366,314	11,644,010
Inventories	1,206	4,721
Trade, bills and other receivables and prepayments	490,393	638,680
Contract assets	756,028	824,714
Structured deposits and derivative financial instruments	68,827	26,000
Note receivables	1,581	944
Prepaid income tax	8,066	27,017
Restricted bank deposits	3,127	52
Time deposit with original maturity over three months	30,160	161,919
Cash and cash equivalents	2,006,926	9,959,963

Consolidated Statement of Financial Position (Cont'd)



	As of December 31,	
(RMB 000s)	2019	
CURRENT LIABILITIES	1,811,986	1,139,337
Trade and other payables	428,471	529,546
Contract liabilities	398,240	484,643
Borrowings	864,863	-
Income tax payables	70,293	72,858
Lease liabilities	50,119	52,290
NON-CURRENT LIABILITIES	234,712	508,245
Borrowings	36,500	-
Lease liabilities	132,151	279,021
Other long-term liabilities	20,343	97,494
Deferred tax liabilities	45,718	131,730
NET ASSETS	5,521,278	17,858,477
TOTAL EQUITY	5,521,278	17,858,477
Share capital	749,508	872,484
Treasury shares	(211,224)	(157,912)
Reserves	3,708,558	15,439,252
Equity attributable to owners of the Company	4,246,842	16,153,824
Non-controlling interests	1,274,436	1,704,653



300347.SZ 3347.HK

Hangzhou Tigermed Consulting Co., Ltd. www.tigermedgrp.com